This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Aronson JK. Meyler’s side effects of drugs (sixteenth edition). The international encyclopedia of adverse drug reactions and interactions. Dexketoprofen. Oxford (UK): Elsevier; 2016. p. 888–890. https://doi.org/10.1016/B978-0-444-53717-1.01685-1AronsonJK.Meyler’s side effects of drugs (sixteenth edition). The international encyclopedia of adverse drug reactions and interactions..Oxford (UK):Elsevier;2016. p.888–890. https://doi.org/10.1016/B978-0-444-53717-1.01685-1Open DOISearch in Google Scholar
Bacchi S, Palumbo P, Sponta A, Coppolino MF. Clinical pharmacology of non-steroidal anti-inflammatory drugs: a review. Anti-inflamm Antiallergy Agents Med Chem. 2012;11(1):52–64. https://doi.org/10.2174/187152312803476255BacchiSPalumboPSpontaACoppolinoMF.Clinical pharmacology of non-steroidal anti-inflammatory drugs: a review..2012;11(1):52–64. https://doi.org/10.2174/187152312803476255Open DOISearch in Google Scholar
Bjarnason I, Scarpignato C, Holmgren E, Olszewski M, Rainsford KD, Lanas A. Mechanisms of damage to the gastrointestinal tract from nonsteroidal anti-inflammatory drugs. Gastroenterology. 2018 Feb;154(3):500–514. https://doi.org/10.1053/j.gastro.2017.10.049BjarnasonIScarpignatoCHolmgrenEOlszewskiMRainsfordKDLanasA.Mechanisms of damage to the gastrointestinal tract from nonsteroidal anti-inflammatory drugs..2018Feb;154(3):500–514. https://doi.org/10.1053/j.gastro.2017.10.049Open DOISearch in Google Scholar
Blaabjerg S, Artzi DM, Aabenhus R. Probiotics for the prevention of antibiotic-associated diarrhea in outpatients – A systematic review and meta-analysis. Antibiotics. 2017 Oct;6(4):21. https://doi.org/10.3390/antibiotics6040021BlaabjergSArtziDMAabenhusR.Probiotics for the prevention of antibiotic-associated diarrhea in outpatients – A systematic review and meta-analysis..2017Oct;6(4):21. https://doi.org/10.3390/antibiotics6040021Open DOISearch in Google Scholar
Caillé G, Besner JG, Lacasse Y, Vézina M. Pharmacokinetic characteristics of ketoprofen suppositories. Biopharm Drug Dispos. 1980 Apr–Jun;1(4):195–201. https://doi.org/10.1002/bdd.2510010407CailléGBesnerJGLacasseYVézinaM.Pharmacokinetic characteristics of ketoprofen suppositories..1980Apr–Jun;1(4):195–201. https://doi.org/10.1002/bdd.2510010407Open DOISearch in Google Scholar
Cheng X, Huang F, Zhang K, Yuan X, Song C. Effects of nonsteroidal anti-inflammatory and antibiotic drugs on the oral immune system and oral microbial composition in rats. Biochem Biophys Res Commun. 2018;507:420–425. https://doi.org/10.1016/j.bbrc.2018.11.054ChengXHuangFZhangKYuanXSongC.Effects of nonsteroidal anti-inflammatory and antibiotic drugs on the oral immune system and oral microbial composition in rats..2018;507:420–425. https://doi.org/10.1016/j.bbrc.2018.11.054Open DOISearch in Google Scholar
CLSI. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard – 10th ed. CLSI document M07-A10. Wayne (USA): Clinical and Laboratory Standards Institute; 2015.CLSI.; approved standard – 10th ed. CLSI document M07-A10.Wayne (USA):Clinical and Laboratory Standards Institute;2015.Search in Google Scholar
Elshaer SL, Shaldam MA, Shaaban MI. Ketoprofen, piroxicam and indomethacin-suppressed quorum sensing and virulence factors in Acinetobacter baumannii. J Appl Microbiol. 2022 Oct; 133(4): 2182–2197. https://doi.org/10.1111/jam.15609ElshaerSLShaldamMAShaabanMI.Ketoprofen, piroxicam and indomethacin-suppressed quorum sensing and virulence factors in Acinetobacter baumannii..2022Oct;133(4):2182–2197. https://doi.org/10.1111/jam.15609Open DOISearch in Google Scholar
EMA. Ipren, suppositories 125 mg [Internet]. Amsterdam (The Netherlands): European Medicines Agency; 2003 [cited 2023 Jun 30]. Available from http://art45-paediatric-studies-docs.ema.europa.eu/GROUP%20I/ibuprofen/ibuprofen%20573-CHC-9127-001.pdfEMA..Amsterdam (The Netherlands):European Medicines Agency;2003[cited 2023 Jun 30].Available from http://art45-paediatric-studies-docs.ema.europa.eu/GROUP%20I/ibuprofen/ibuprofen%20573-CHC-9127-001.pdfSearch in Google Scholar
Endo H, Higurashi T, Hosono K, Sakai E, Sekino Y, Iida H, Sakamoto Y, Koide T, Takahashi H, Yoneda M, et al. Efficacy of Lactobacillus casei treatment on small bowel injury in chronic low-dose aspirin users: a pilot randomized controlled study. J Gastroenterol. 2011 Jul;46(7):894–905. https://doi.org/10.1007/s00535-011-0410-1EndoHHigurashiTHosonoKSakaiESekinoYIidaHSakamotoYKoideTTakahashiHYonedaM.Efficacy of Lactobacillus casei treatment on small bowel injury in chronic low-dose aspirin users: a pilot randomized controlled study..2011Jul;46(7):894–905. https://doi.org/10.1007/s00535-011-0410-1Open DOISearch in Google Scholar
Gajdacs M, Spengler G. The role of drug repurposing in the development of novel antimicrobial drugs: non-antibiotic pharmacological agents as quorum sensing-inhibitors. Antibiotics. 2019;8(4):270. https://doi.org/10.3390/antibiotics8040270GajdacsMSpenglerG.The role of drug repurposing in the development of novel antimicrobial drugs: non-antibiotic pharmacological agents as quorum sensing-inhibitors..2019;8(4):270. https://doi.org/10.3390/antibiotics8040270Open DOISearch in Google Scholar
Gonzalez-Canudas J, Garcia-Aguirre LJ, Medina-Nolasco A, Ruiz-Olmedo MI, Reyes LJM, Zambrano-Tapia L, Romero-Antonio Y, Molina-Pérez A, Amador-Hernández AG. Bioequivalence evaluation of two oral formulations of dexketoprofen-trometamol (solution and tablets) in healthy subjects: Results from a randomized, single-blind, crossover study. Trends Med. 2019;19:1–5. https://doi.org/10.15761/TiM.1000176Gonzalez-CanudasJGarcia-AguirreLJMedina-NolascoARuiz-OlmedoMIReyesLJMZambrano-TapiaLRomero-AntonioYMolina-PérezAAmador-HernándezAG.Bioequivalence evaluation of two oral formulations of dexketoprofen-trometamol (solution and tablets) in healthy subjects: Results from a randomized, single-blind, crossover study..2019;19:1–5. https://doi.org/10.15761/TiM.1000176Open DOISearch in Google Scholar
Janssen GM, Venema JF. Ibuprofen: Plasma concentrations in man. J Int Med Res. 1985;13(1):68–73. https://doi.org/10.1177/030006058501300110JanssenGMVenemaJF.Ibuprofen: Plasma concentrations in man..1985;13(1):68–73. https://doi.org/10.1177/030006058501300110Open DOISearch in Google Scholar
Jiménez-Serna A, Hernandez-Sánchez H. Effect of different antibiotics and non-steroidal anti-inflammatory drugs on the growth of Lactobacillus casei Shirota. Curr Microbiol. 2011 Mar;62(3): 1028–1033. https://doi.org/10.1007/s00284-010-9819-7Jiménez-SernaAHernandez-SánchezH.Effect of different antibiotics and non-steroidal anti-inflammatory drugs on the growth of Lactobacillus casei Shirota..2011Mar;62(3):1028–1033. https://doi.org/10.1007/s00284-010-9819-7Open DOISearch in Google Scholar
Kerry GR, Patra JK, Gouda S, Park Y, Shin HS, Das G. Benefaction of probiotics for human health: A review. J Food Drug Anal. 2018 Jul;26(3):927–939. https://doi.org/10.1016/j.jfda.2018.01.002KerryGRPatraJKGoudaSParkYShinHSDasG.Benefaction of probiotics for human health: A review..2018Jul;26(3):927–939. https://doi.org/10.1016/j.jfda.2018.01.002Open DOISearch in Google Scholar
Klopper KB, Deane SM, Dicks LMT. Aciduric strains of Lactobacillus reuteri and Lactobacillus rhamnosus, isolated from human feces, have strong adhesion and aggregation properties. Probiotics Antimicrob Proteins. 2018 Mar;10(1):89–97. https://doi.org/10.1007/s12602-017-9307-5KlopperKBDeaneSMDicksLMT.Aciduric strains of Lactobacillus reuteri and Lactobacillus rhamnosus, isolated from human feces, have strong adhesion and aggregation properties..2018Mar;10(1):89–97. https://doi.org/10.1007/s12602-017-9307-5Open DOISearch in Google Scholar
Kmiec N, Welnicka-Jaskiewicz M, Jassem J. [Nonsteroidal anti-inflammatory drugs in the prevention and treatment of colorectal cancer] (in Polish). J Oncol. 2014;64(2):175–179. https://doi.org/10.5603/NJO.2014.0024KmiecNWelnicka-JaskiewiczMJassemJ.[Nonsteroidal anti-inflammatory drugs in the prevention and treatment of colorectal cancer] (in Polish)..2014;64(2):175–179. https://doi.org/10.5603/NJO.2014.0024Open DOISearch in Google Scholar
Kruszewska H, Zareba T, Kociszewska A, Tyski S. Activity of selected non-antibiotic medicinal preparations against standard microorganisms including bacterial probiotic strains. Acta Pol Pharm Drug Res. 2021;78(2):179–185. https://doi.org/10.32383/appdr/136439KruszewskaHZarebaTKociszewskaATyskiS.Activity of selected non-antibiotic medicinal preparations against standard microorganisms including bacterial probiotic strains..2021;78(2):179–185. https://doi.org/10.32383/appdr/136439Open DOISearch in Google Scholar
Kruszewska H, Zaruba T, Tyski S. Examination of antimicrobial activity of selected non-antibiotic medicinal preparations. Acta Pol Pharm Drug Res. 2012;69(6):1368–1371.KruszewskaHZarubaTTyskiS.Examination of antimicrobial activity of selected non-antibiotic medicinal preparations..2012;69(6):1368–1371.Search in Google Scholar
Lagadinou M, Onisor MO, Rigas A, Musetescu DV, Gkentzi D, Assimakopoulos SF, Panos G, Marangos M. Antimicrobial properties on non-antibiotic drugs in the era of increased bacterial resistance. Antibiotics. 2020 Mar;9(3):107. https://doi.org/10.3390/antibiotics9030107LagadinouMOnisorMORigasAMusetescuDVGkentziDAssimakopoulosSFPanosGMarangosM.Antimicrobial properties on non-antibiotic drugs in the era of increased bacterial resistance..2020Mar;9(3):107. https://doi.org/10.3390/antibiotics9030107Open DOISearch in Google Scholar
Laudy AE, Kulinska E, Tyski S. The impact of efflux pump inhibitors on the activity of selected non-antibiotic medicinal products against Gram-negative bacteria. Molecules. 2017 Jan;22(1):114. https://doi.org/10.3390/molecules22010114LaudyAEKulinskaETyskiS.The impact of efflux pump inhibitors on the activity of selected non-antibiotic medicinal products against Gram-negative bacteria..2017Jan;22(1):114. https://doi.org/10.3390/molecules22010114Open DOISearch in Google Scholar
Laudy AE, Mrowka A, Krajewska J, Tyski S. The influence of efflux pump inhibitors on the activity of non-antibiotics NSAIDS against Gram-negative rods. PLoS One. 2016 Jan;11(1):e0147131. https://doi.org/10.1371/journal.pone.0147131LaudyAEMrowkaAKrajewskaJTyskiS.The influence of efflux pump inhibitors on the activity of non-antibiotics NSAIDS against Gram-negative rods..2016Jan;11(1):e0147131. https://doi.org/10.1371/journal.pone.0147131Open DOISearch in Google Scholar
Laudy AE. Non-antibiotics, efflux pumps and drug resistance of Gram-negative rods. Pol J Microbiol. 2018 Jun;67(2):129–135. https://doi.org/10.21307/pjm-2018-017LaudyAE.Non-antibiotics, efflux pumps and drug resistance of Gram-negative rods..2018Jun;67(2):129–135. https://doi.org/10.21307/pjm-2018-017Open DOISearch in Google Scholar
Lázár B, László SB, Hutka B, Toth AS, Mohammadzadeh A, Berekmeri E, Ägg B, Balogh M, Sajtos V, Kiraly K, et al. A comprehensive time course and correlation analysis of indomethacin-induced inflammation, bile acid alterations and dysbiosis in the rat small intestine. Biochem Pharmacol. 2021 Aug;190:114590. https://doi.org/10.1016/j.bcp.2021.114590LázárBLászlóSBHutkaBTothASMohammadzadehABerekmeriEÄggBBaloghMSajtosVKiralyK.A comprehensive time course and correlation analysis of indomethacin-induced inflammation, bile acid alterations and dysbiosis in the rat small intestine..2021Aug;190:114590. https://doi.org/10.1016/j.bcp.2021.114590Open DOISearch in Google Scholar
Leäo C, Borges A, Simões M. NSAIDs as a drug repurposing strategy for biofilm control. Antibiotics. 2020 Sep;9(9):591. https://doi.org/10.3390/antibiotics9090591LeäoCBorgesASimõesM.NSAIDs as a drug repurposing strategy for biofilm control..2020Sep;9(9):591. https://doi.org/10.3390/antibiotics9090591Open DOISearch in Google Scholar
Liang X, Bittinger K, Li X, Abernethy DR, Bushman FD, Fitz Gerald GA. Bidirectional interactions between indomethacin and the murine intestinal microbiota. elife. 2015 Dec;4:e08973. https://doi.org/10.7554/eLife.08973LiangXBittingerKLiXAbernethyDRBushmanFDFitz GeraldGA.Bidirectional interactions between indomethacin and the murine intestinal microbiota..2015Dec;4:e08973. https://doi.org/10.7554/eLife.08973Open DOISearch in Google Scholar
Maier L, Pruteanu M, Kuhn M, Zeller G, Telzerow A, Anderson EE, Brochado AR, Fernandez KC, Dose H, Mori H, et al. Extensive impact of non-antibiotic drugs on human gut bacteria. Nature. 2018 Mar 29;555(7698):623–628. https://doi.org/10.1038/nature25979MaierLPruteanuMKuhnMZellerGTelzerowAAndersonEEBrochadoARFernandezKCDoseHMoriH.Extensive impact of non-antibiotic drugs on human gut bacteria..2018Mar29;555(7698):623–628. https://doi.org/10.1038/nature25979Open DOISearch in Google Scholar
Markowiak-Kopec P, Slizewska K. The effect of probiotics on the production of short-chain fatty acids by human intestinal microbiome. Nutrients. 2020 Apr;12(4):1107. https://doi.org/10.3390/nu12041107Markowiak-KopecPSlizewskaK.The effect of probiotics on the production of short-chain fatty acids by human intestinal microbiome..2020Apr;12(4):1107. https://doi.org/10.3390/nu12041107Open DOISearch in Google Scholar
Maseda D, Ricciotti E. NSAID-gut microbiota interactions. Front Pharmacol. 2020 Aug;11:1153. https://doi.org/10.3389/fphar.2020.01153MasedaDRicciottiE.NSAID-gut microbiota interactions..2020Aug;11:1153. https://doi.org/10.3389/fphar.2020.01153Open DOISearch in Google Scholar
Montrose DC, Zhou XK, McNally EM, Sue E, Yantiss RK, Gross SS, Leve ND, Karoly ED, Suen CS, Ling L, et al. Celecoxib alters the intestinal microbiota and metabolome in association with reducing polyp burden. Cancer Prev Res (Phila). 2016 Sep;9(9):721–731. https://doi.org/10.1158/1940-6207.CAPR-16-0095MontroseDCZhouXKMcNallyEMSueEYantissRKGrossSSLeveNDKarolyEDSuenCSLingL.Celecoxib alters the intestinal microbiota and metabolome in association with reducing polyp burden..2016Sep;9(9):721–731. https://doi.org/10.1158/1940-6207.CAPR-16-0095Open DOISearch in Google Scholar
Nadatani Y, Watanabe T, Suda W, Nakata A, Matsumoto Y, Kosaka S, Higashimori A, Otani K, Hosomi S, Tanakaet F, et al. Gastric acid inhibitor aggravates indomethacin-induced small intestinal injury via reducing Lactobacillus johnsonii. Sci Rep. 2019 Nov; 9(1):17490. https://doi.org/10.1038/s41598-019-53559-7NadataniYWatanabeTSudaWNakataAMatsumotoYKosakaSHigashimoriAOtaniKHosomiSTanakaetF.Gastric acid inhibitor aggravates indomethacin-induced small intestinal injury via reducing Lactobacillus johnsonii..2019Nov;9(1):17490. https://doi.org/10.1038/s41598-019-53559-7Open DOISearch in Google Scholar
Nagelschmitz J, Blunck M, Kraetzschmar J, Ludwig M, Wensing G, Hohlfeld T. Pharmacokinetics and pharmacodynamicsof acetylsalicylic acid after intravenous and oral administration to healthy volunteers. Clin Pharmacol. 2014 Mar;6:51–59. https://doi.org/10.2147/CPAA.S47895NagelschmitzJBlunckMKraetzschmarJLudwigMWensingGHohlfeldT.Pharmacokinetics and pharmacodynamicsof acetylsalicylic acid after intravenous and oral administration to healthy volunteers..2014Mar;6:51–59. https://doi.org/10.2147/CPAA.S47895Open DOISearch in Google Scholar
Nair BM, Cheung KJ Jr, Griffith A, Burns JL. Salicylate induces an antibiotic efflux pump in Burkholderia cepacia complex genomovar III (B. cenocepacia). J Clin Invest. 2004 Feb;113(3):464–473. https://doi.org/10.1172/JCI19710NairBMCheungKJJrGriffithABurnsJL.Salicylate induces an antibiotic efflux pump in Burkholderia cepacia complex genomovar III (B. cenocepacia)..2004Feb;113(3):464–473. https://doi.org/10.1172/JCI19710Open DOISearch in Google Scholar
Novartis Pharmaceuticals UK Ltd.Voltarol 12.5 mg Suppositories summary of product characteristics [Internet]. Electronic Medicines Compendium; 2023 [cited 2023 Jun 30]. Available from https://www.medicines.org.uk/emc/product/1044/smpcNovartis Pharmaceuticals UK Ltd..Electronic Medicines Compendium;2023[cited 2023 Jun 30].Available from https://www.medicines.org.uk/emc/product/1044/smpcSearch in Google Scholar
Phillips WJ, Currier BL. Analgesic pharmacology: II. Specific analgesics. J Am Acad Orthop Surg. 2004 Jul-Aug;12(4):221–233. https://doi.org/10.5435/00124635-200407000-00003PhillipsWJCurrierBL.Analgesic pharmacology: II. Specific analgesics..2004Jul-Aug;12(4):221–233. https://doi.org/10.5435/00124635-200407000-00003Open DOISearch in Google Scholar
Roda A, Sabatini L, Mirasoli M, Baraldini M, Roda E. Bioavailability of a new ketoprofen formulation for once-daily oral administration. Int J Pharm. 2002 Jul;241(1):165–172. https://doi.org/10.1016/s0378-5173(02)00230-2RodaASabatiniLMirasoliMBaraldiniMRodaE.Bioavailability of a new ketoprofen formulation for once-daily oral administration..2002Jul;241(1):165–172. https://doi.org/10.1016/s0378-5173(02)00230-2Open DOISearch in Google Scholar
Sarzi-Puttini P, Atzeni F, Lanata L, Bagnasco M. Efficacy of ketoprofen vs. ibuprofen and diclofenac: a systematic review of the literature and meta-analysis. Clin Exp Rheumatol. 2013 Sep–Oct; 31(5):731–738.Sarzi-PuttiniPAtzeniFLanataLBagnascoM.Efficacy of ketoprofen vs. ibuprofen and diclofenac: a systematic review of the literature and meta-analysis..2013Sep–Oct;31(5):731–738.Search in Google Scholar
Scaroni C, Mazzoni PL, D’Amico E, Benvenuti C, Hind ID. Pharmacokinetics of oral and rectal flurbiprofen in children. Eur J Clin Pharmacol. 1984;27(3):367–369. https://doi.org/10.1007/BF00542178 Standards Institute; 2015.ScaroniCMazzoniPLD’AmicoEBenvenutiCHindID.Pharmacokinetics of oral and rectal flurbiprofen in children..1984;27(3):367–369. https://doi.org/10.1007/BF00542178Standards Institute;2015.Open DOISearch in Google Scholar
Suzuki T, Masui A, Nakamura J, Shiozawa H, Aoki J, Nakae H, Tsuda S, Imai J, Hideki O, Matsushima M, et al. Yogurt containing Lactobacillus gasseri mitigates aspirin-induced small bowel injuries: A prospective, randomized, double-blind, placebo-controlled trial. Digestion. 2017;95(1):49–54. https://doi.org/10.1159/000452361SuzukiTMasuiANakamuraJShiozawaHAokiJNakaeHTsudaSImaiJHidekiOMatsushimaM.Yogurt containing Lactobacillus gasseri mitigates aspirin-induced small bowel injuries: A prospective, randomized, double-blind, placebo-controlled trial..2017;95(1):49–54. https://doi.org/10.1159/000452361Open DOISearch in Google Scholar
Syer SD, Blackler RW, Martin R, de Palma G, Rossi L, Verdu E, Bercik P, Surette MG, Aucouturier A, Langella P, et al. NSAID enteropathy and bacteria: A complicated relationship. J Gastroenterol. 2015 Apr;50(4):387–393. https://doi.org/10.1007/s00535-014-1032-1SyerSDBlacklerRWMartinRde PalmaGRossiLVerduEBercikPSuretteMGAucouturierALangellaP.NSAID enteropathy and bacteria: A complicated relationship..2015Apr;50(4):387–393. https://doi.org/10.1007/s00535-014-1032-1Open DOISearch in Google Scholar
Tyski S. Non-antibiotics – drugs with additional antimicrobial activity. Acta Pol Pharm Drug Res. 2003;60(5):401–404.TyskiS.Non-antibiotics – drugs with additional antimicrobial activity..2003;60(5):401–404.Search in Google Scholar
Valentovic M. Flurbiprofen. In: Enna SJ and Bylun DB, editors. xPharm: The comprehensive pharmacology reference. New York (USA): Elsevier; 2007. p. 1–6. https://doi.org/10.1016/B978-008055232-3.61777-5ValentovicM.Flurbiprofen. In:EnnaSJ and BylunDB, editors..New York (USA):Elsevier;2007. p.1–6. https://doi.org/10.1016/B978-008055232-3.61777-5Open DOISearch in Google Scholar
Wang X, Tang Q, Hou H, Zhang W, Li M, Chen D, Gu Y, Wang B, Hou J, Liu Y, et al. Gut microbiota in NSAID enteropathy: New insights from inside. Front Cell Infect Microbiol. 2021 Jul;11:679396. https://doi.org/10.3389/fcimb.2021.679396WangXTangQHouHZhangWLiMChenDGuYWangBHouJLiuY.Gut microbiota in NSAID enteropathy: New insights from inside..2021Jul;11:679396. https://doi.org/10.3389/fcimb.2021.679396Open DOISearch in Google Scholar
Watanabe T, Nishio H, Tanigawa T, Yamagami H, Okazaki H, Watanabe K, Tominaga K, Fujiwara Y, Oshitani N, Asahara T, et al. Probiotic Lactobacillus casei strain Shirota prevents indomethacin-induced small intestinal injury: involvement of lactic acid. Am J Physiol Gastrointest Liver Physiol. 2009 Sep;297(3):G506-G513. https://doi.org/10.1152/ajpgi.90553.2008WatanabeTNishioHTanigawaTYamagamiHOkazakiHWatanabeKTominagaKFujiwaraYOshitaniNAsaharaT.Probiotic Lactobacillus casei strain Shirota prevents indomethacin-induced small intestinal injury: involvement of lactic acid..2009Sep;297(3):G506-G513. https://doi.org/10.1152/ajpgi.90553.2008Open DOISearch in Google Scholar
Willis JV, Kendall MJ, Flinn RM, Thornhill DP, Welling PG. The pharmacokinetics of diclofenac sodium following intravenous and oral administration. Eur J Clin Pharmacol. 1979;16(6):405–410. https://doi.org/10.1007/BF00568201WillisJVKendallMJFlinnRMThornhillDPWellingPG.The pharmacokinetics of diclofenac sodium following intravenous and oral administration..1979;16(6):405–410. https://doi.org/10.1007/BF00568201Open DOISearch in Google Scholar
Yilmaz B, Erdem AF. Determination of flurbiprofen in human plasma by high-performance liquid chromatography. J Chromatogr Sci. 2015 Oct;53(9):1443–1448. https://doi.org/10.1093/chromsci/bmv032YilmazBErdemAF.Determination of flurbiprofen in human plasma by high-performance liquid chromatography..2015Oct;53(9):1443–1448. https://doi.org/10.1093/chromsci/bmv032Open DOISearch in Google Scholar
Yu T, Lao X, Zheng H. Influencing COX-2 activity by COX related pathways in inflammation and cancer. Mini Rev Med Chem. 2016; 16(15):1230–1243. https://doi.org/10.2174/1389557516666160505115743YuTLaoXZhengH.Influencing COX-2 activity by COX related pathways in inflammation and cancer..2016;16(15):1230–1243. https://doi.org/10.2174/1389557516666160505115743Open DOISearch in Google Scholar
Zádori ZS, Kiraly K, Al-Khrasani M, Gyires K. Interactions between NSAIDs, opioids and the gut microbiota – Future perspectives in the management of inflammation and pain. Pharmacol Ther. 2023 Jan;241:108327. https://doi.org/10.1016/j.pharmthera.2022.108327ZádoriZSKiralyKAl-KhrasaniMGyiresK.Interactions between NSAIDs, opioids and the gut microbiota – Future perspectives in the management of inflammation and pain..2023Jan;241:108327. https://doi.org/10.1016/j.pharmthera.2022.108327Open DOISearch in Google Scholar
Zawistowska-Rojek A, Tyski S. How to improve health with biological agents – Narrative review. Nutrients. 2022 Apr;14(9):1700. https://doi.org/10.3390/nu14091700Zawistowska-RojekATyskiS.How to improve health with biological agents – Narrative review..2022Apr;14(9):1700. https://doi.org/10.3390/nu14091700Open DOISearch in Google Scholar
Zimmermann P, Curtis N. Antimicrobial effects of antipyretics. Antimicrob Agents Chemother. 2017 Mar 24;61(4):e02268-16. https://doi.org/10.1128/AAC.02268-16ZimmermannPCurtisN.Antimicrobial effects of antipyretics..2017Mar24;61(4):e02268-16. https://doi.org/10.1128/AAC.02268-16Open DOISearch in Google Scholar